PTC Historical Income Statement
| PTCT Stock | USD 32.14 3.57 12.50% |
Historical analysis of PTC Therapeutics income statement accounts such as Depreciation And Amortization of 248.4 M, Selling General Administrative of 366.4 M, Gross Profit of 682.2 M or Other Operating Expenses of 1.4 B can show how well PTC Therapeutics performed in making a profits. Evaluating PTC Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of PTC Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining PTC Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether PTC Therapeutics is a good buy for the upcoming year.
PTC |
About PTC Income Statement Analysis
PTC Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to PTC Therapeutics shareholders. The income statement also shows PTC investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
PTC Therapeutics Income Statement Chart
PTC Therapeutics Income Statement is one of the three primary financial statements used for reporting PTC's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of PTC Therapeutics revenue and expense. PTC Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, PTC Therapeutics' Total Operating Expenses is comparatively stable compared to the past year. Reconciled Depreciation is likely to gain to about 204.5 M in 2024, whereas EBITDA is likely to drop (118.5 M) in 2024. Add Fundamental
Total Revenue
Total revenue comprises all receipts PTC Therapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of PTC Therapeutics. It is also known as PTC Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from PTC Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into PTC Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PTC Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy PTC Stock please use our How to Invest in PTC Therapeutics guide.At this time, PTC Therapeutics' Total Operating Expenses is comparatively stable compared to the past year. Reconciled Depreciation is likely to gain to about 204.5 M in 2024, whereas EBITDA is likely to drop (118.5 M) in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Research Development | 540.7M | 651.5M | 666.6M | 699.9M | Total Revenue | 538.6M | 698.8M | 937.8M | 984.7M |
PTC Therapeutics income statement Correlations
Click cells to compare fundamentals
PTC Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
PTC Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 12.5M | 56.4M | 86.0M | 90.9M | 129.2M | 135.6M | |
| Total Revenue | 307.0M | 380.8M | 538.6M | 698.8M | 937.8M | 984.7M | |
| Research Development | 257.5M | 477.6M | 540.7M | 651.5M | 666.6M | 699.9M | |
| Cost Of Revenue | 12.1M | 18.9M | 32.3M | 44.7M | 288.1M | 302.5M | |
| Depreciation And Amortization | 76.0M | 170.1M | (3.1M) | 67.3M | 236.6M | 248.4M | |
| Selling General Administrative | 202.5M | 245.2M | 285.3M | 300.1M | 349.0M | 366.4M | |
| Gross Profit | 294.8M | 361.8M | 506.3M | 654.1M | 649.7M | 682.2M | |
| Other Operating Expenses | 499.8M | 778.6M | 913.5M | 1.1B | 1.3B | 1.4B | |
| Operating Income | (192.8M) | (397.9M) | (374.9M) | (439.9M) | (349.4M) | (331.9M) | |
| Ebit | (192.8M) | (397.9M) | (374.9M) | (439.9M) | (349.4M) | (331.9M) | |
| Ebitda | (116.8M) | (227.8M) | (378.1M) | (372.6M) | (112.8M) | (118.5M) | |
| Total Operating Expenses | 487.6M | 759.7M | 881.2M | 1.1B | 999.1M | 1.0B | |
| Income Before Tax | (239.9M) | (402.9M) | (518.3M) | (587.5M) | (696.1M) | (661.3M) | |
| Total Other Income Expense Net | (47.1M) | (5.1M) | (143.4M) | (147.6M) | (346.7M) | (329.4M) | |
| Net Income Applicable To Common Shares | (251.6M) | (438.2M) | (523.9M) | (559.0M) | (503.1M) | (478.0M) | |
| Net Income | (251.6M) | (438.2M) | (523.9M) | (559.0M) | (626.6M) | (595.3M) | |
| Income Tax Expense | 11.7M | 35.2M | 5.6M | (28.5M) | (69.5M) | (66.0M) | |
| Net Income From Continuing Ops | (251.6M) | (438.2M) | (523.9M) | (559.0M) | (641.7M) | (609.6M) | |
| Non Operating Income Net Other | 13.7M | 85.2M | (57.9M) | (49.2M) | (44.3M) | (42.1M) | |
| Tax Provision | 11.7M | 35.2M | 5.6M | (28.5M) | (87.1M) | (82.7M) | |
| Net Interest Income | (12.5M) | (56.4M) | (86.0M) | (90.9M) | (109.4M) | (103.9M) | |
| Reconciled Depreciation | 32.2M | 43.5M | 64.1M | 128.8M | 194.8M | 204.5M |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as PTC Therapeutics using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PTC Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy PTC Stock please use our How to Invest in PTC Therapeutics guide.Note that the PTC Therapeutics information on this page should be used as a complementary analysis to other PTC Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Complementary Tools for PTC Stock analysis
When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |
Is PTC Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PTC Therapeutics. If investors know PTC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PTC Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.37) | Revenue Per Share 12.281 | Quarterly Revenue Growth (0.05) | Return On Assets (0.10) | Return On Equity (77.40) |
The market value of PTC Therapeutics is measured differently than its book value, which is the value of PTC that is recorded on the company's balance sheet. Investors also form their own opinion of PTC Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is PTC Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PTC Therapeutics' market value can be influenced by many factors that don't directly affect PTC Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PTC Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if PTC Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PTC Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.